Dosing strategies aimed at gradually raising drug levels in the body, instead of increasing levels all at once, may help…
Articles by Marisa Horak, MS
When Karla Dzienkowski’s daughter started experiencing abnormal restlessness and daytime sleepiness as a preteen, Dzienkowski initially assumed that these…
The U.S. Food and Drug Administration (FDA) has approved Takeda‘s oral therapy Orzeyful (oveporexton) for adults with narcolepsy…
Looking at patterns of electrical activity in the brain during sleep may help to distinguish between children with narcolepsy…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Lu AH69593, an experimental oral therapy…
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of Axsome Therapeutics‘ experimental…
Long-term treatment with the experimental oral therapy alixorexton safely improved wakefulness, eased fatigue, and boosted cognition for people with…
Type 1 narcolepsy has long been linked to the loss of nerve cells called hypocretin neurons in a brain…
In adults with narcolepsy type 1 (NT1), a specific brain region called the hypothalamus is smaller than in people…